Puma Biotechnology, Inc. cash flow to debt ratio of 146.44% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Puma Biotechnology, Inc.'s free cash flow has increased 7.38% from $38.86M last year to $41.73M, signaling increasing performance

Puma Biotechnology, Inc.'s debt to equity ratio is 0.12, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Puma Biotechnology, Inc.'s debt has decreased relative to shareholder equity from 0.80 last year to 0.12 today, signaling strengthened financials

Puma Biotechnology, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Puma Biotechnology, Inc.'s interest coverage ratio of 5.70 indicates that earnings with good margin can cover interest payments on company debt

Puma Biotechnology, Inc.'s profit margin has decreased (-18.30%) in the last year from 13.14% to 10.73%, signaling decreasing performance

Puma Biotechnology, Inc.'s short-term assets of $162.69M exceed its short-term liabilities of $81.25M

Puma Biotechnology, Inc.'s return on assets of 12.65% is higher than the 5.00% threshold, indicating efficient asset utilization

Puma Biotechnology, Inc.'s return on equity of 20.37%, is higher than 15.00%, indicating good performance

Puma Biotechnology, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Puma Biotechnology, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings

Puma Biotechnology, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Puma Biotechnology, Inc. has a free cash flow yield of 10.11%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Puma Biotechnology, Inc.'s yearly earnings has increased 2.75% since last year from $30.28M to $31.11M, signaling increasing performance

Puma Biotechnology, Inc.'s yearly revenue has decreased -0.91% since last year from $230.47M to $228.37M, signaling decreasing performance

ROIC 17.12% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Puma Biotechnology, Inc.'s 3-year revenue CAGR of 0.05% is positive, indicating growing revenue over the past 3 years

Puma Biotechnology, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Puma Biotechnology, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity

Puma Biotechnology, Inc. has insufficient data to evaluate this check.

Puma Biotechnology, Inc. has an earnings yield of 5.91%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Puma Biotechnology, Inc. is overvalued relative to its fair value price of 7.37 based on EBITDA multiple model

Puma Biotechnology, Inc. has an EV/EBITDA ratio of 8.74x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Puma Biotechnology, Inc. is overvalued relative to its fair value price of 5.32 based on Earnings Fair Value model

Puma Biotechnology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Puma Biotechnology, Inc. has a price-to-book ratio of 3.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Puma Biotechnology, Inc. has a price-to-sales ratio of 1.82x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue